Generics Firms Advised To Engage Early In Europe's Referral Process
Generic firms are now covered by the pharmacovigilance referral process and participation by their reg affairs staff can help them anticipate, and weigh in on, resulting requirements for additional studies or other measures.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.